# Stem Cells Sector

Canonical URL: https://biopharmsignal.com/sector/stem-cells

Stem Cells includes companies developing therapies or regenerative approaches based on stem cell biology. These businesses are often followed for their potential in tissue repair, rare disease, and chronic degenerative conditions, though clinical translation can be complex and slow.

Companies currently grouped under Stem Cells: 8

## Recent Sector News

- 2026-10-07 12:00 EST — JSPR — [Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants](https://biopharmsignal.com/news/JSPR/jasper-therapeutics-announces-commencement-of-an-offer-to-purchase-outstanding-w-377618a3) — Source: Jasper Therapeutics
- 2026-09-15 20:05 EST — JSPR — [Jasper Therapeutics Announces Key Regulatory and Clinical Appointments](https://biopharmsignal.com/news/JSPR/jasper-therapeutics-announces-key-regulatory-and-clinical-appointments-840f0f28) — Source: Jasper Therapeutics
- 2026-09-09 12:00 EST — JSPR — [Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference](https://biopharmsignal.com/news/JSPR/jasper-therapeutics-to-present-at-the-h-c-wainwright-28th-annual-global-investme-59ca56a8) — Source: Jasper Therapeutics
- 2026-08-24 12:15 EST — BCLI — [BrainStorm Executive Leadership to Participate in DUPHAT 2026; Executive Chairman Peter J. Pitts Invited to Deliver Two Keynote Addresses and Moderate Panel Sessions](https://biopharmsignal.com/news/BCLI/brainstorm-executive-leadership-to-participate-in-duphat-2026-executive-chairman-5aaec09e) — Source: Brainstorm Cell Therapeutics Inc.
- 2026-08-14 20:00 EST — BCLI — [BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/BCLI/brainstorm-cell-therapeutics-announces-second-quarter-2026-financial-results-and-16a4a575) — Source: Brainstorm Cell Therapeutics Inc.
- 2026-08-14 15:00 EST — JSPR — [Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/JSPR/jasper-therapeutics-reports-second-quarter-2026-financial-results-and-provides-c-629b3111) — Source: Jasper Therapeutics
- 2026-07-28 12:00 EST — BCLI — [BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman](https://biopharmsignal.com/news/BCLI/brainstorm-appoints-former-fda-associate-commissioner-peter-j-pitts-as-executive-0d7242f8) — Source: Brainstorm Cell Therapeutics Inc.
- 2026-07-16 21:15 EST — JSPR — [Jasper Therapeutics Announces Merger with Kira Pharmaceuticals](https://biopharmsignal.com/news/JSPR/jasper-therapeutics-announces-merger-with-kira-pharmaceuticals-a3889d24) — Source: Jasper Therapeutics
- 2026-06-04 11:30 EST — PSTV — [Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory](https://biopharmsignal.com/news/PSTV/plus-therapeutics-announces-cap-accreditation-of-cnsider-diagnostics-clinical-laboratory) — Source: PLUS THERAPEUTICS, Inc.
- 2026-06-02 13:00 EST — BCLI — [BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine](https://biopharmsignal.com/news/BCLI/brainstorm-cell-therapeutics-announces-publication-calling-for-updated-fda-approaches-to-als-rare-diseases-and-regenerative-medicine) — Source: Brainstorm Cell Therapeutics Inc.
- 2026-06-02 01:51 EST — MESO — [ASX CEO Connect Presentation](https://biopharmsignal.com/news/MESO/asx-ceo-connect-presentation) — Source: Mesoblast
- 2026-06-01 12:00 EST — JSPR — [Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value](https://biopharmsignal.com/news/JSPR/jasper-therapeutics-announces-exploration-of-strategic-alternatives-to-maximize--09867656) — Source: Jasper Therapeutics
- 2026-05-28 11:45 EST — BCLI — [BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors](https://biopharmsignal.com/news/BCLI/brainstorm-cell-therapeutics-appoints-former-fda-associate-commissioner-peter-j-pitts-to-board-of-directors) — Source: Brainstorm Cell Therapeutics Inc.
- 2026-05-26 11:30 EST — PSTV — [Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases](https://biopharmsignal.com/news/PSTV/plus-cnside-diagnostic-platform-demonstrates-substantial-healthcare-cost-reduction-in-patients-with-leptomeningeal-metastases) — Source: PLUS THERAPEUTICS, Inc.
- 2026-05-19 12:00 EST — BCLI — [BrainStorm Cell Therapeutics Announces Aggregate of $400,000 in Private Placements Priced at Premium to Market](https://biopharmsignal.com/news/BCLI/brainstorm-cell-therapeutics-announces-aggregate-of-400-000-in-private-placements-priced-at-premium-to-market) — Source: Brainstorm Cell Therapeutics Inc.
- 2026-05-19 11:30 EST — PSTV — [Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology](https://biopharmsignal.com/news/PSTV/plus-therapeutics-partners-with-ephemeral-technologies-to-deploy-ai-execution-platform-for-cns-oncology) — Source: PLUS THERAPEUTICS, Inc.
- 2026-05-15 20:05 EST — PSTV — [Plus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial Rollout](https://biopharmsignal.com/news/PSTV/plus-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-update-on-reyobiqtm-clinical-program-and-cnsider-commercial-rollout) — Source: PLUS THERAPEUTICS, Inc.
- 2026-05-15 20:05 EST — BCLI — [BrainStorm Cell Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/BCLI/brainstorm-cell-therapeutics-announces-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: Brainstorm Cell Therapeutics Inc.
- 2026-05-14 20:05 EST — JSPR — [Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/JSPR/jasper-therapeutics-reports-first-quarter-2026-financial-results-and-provides-co-31f86d47) — Source: Jasper Therapeutics
- 2026-05-08 11:30 EST — PSTV — [Plus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal Metastases](https://biopharmsignal.com/news/PSTV/plus-therapeutics-announces-oral-presentation-highlighting-reyobiqtm-clinical-and-translational-data-demonstrating-favorable-safety-survival-and-emerging-immunomodulation-in-leptomeningeal-metastases) — Source: PLUS THERAPEUTICS, Inc.

## Companies

- [BAYRY](https://biopharmsignal.com/company/BAYRY) — Bayer AG
- [BCLI](https://biopharmsignal.com/company/BCLI) — Brainstorm Cell Therapeutics Inc.
- [JSPR](https://biopharmsignal.com/company/JSPR) — Jasper Therapeutics
- [LNTH](https://biopharmsignal.com/company/LNTH) — Lantheus Holdings, Inc.
- [MESO](https://biopharmsignal.com/company/MESO) — Mesoblast
- [OMED](https://biopharmsignal.com/company/OMED) — OncoMed Pharmaceuticals
- [PSTV](https://biopharmsignal.com/company/PSTV) — PLUS THERAPEUTICS, Inc.
- [SCPX](https://biopharmsignal.com/company/SCPX) — Scorpius Holdings